001450484 000__ 06624cam\a2200565\i\4500
001450484 001__ 1450484
001450484 003__ OCoLC
001450484 005__ 20230310004528.0
001450484 006__ m\\\\\o\\d\\\\\\\\
001450484 007__ cr\cn\nnnunnun
001450484 008__ 221021s2022\\\\sz\a\\\\ob\\\\001\0\eng\d
001450484 019__ $$a1348491382
001450484 020__ $$a9783031097379$$q(electronic bk.)
001450484 020__ $$a3031097378$$q(electronic bk.)
001450484 020__ $$z9783031097362
001450484 020__ $$z303109736X
001450484 0247_ $$a10.1007/978-3-031-09737-9$$2doi
001450484 035__ $$aSP(OCoLC)1348286800
001450484 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCF$$dOCLCQ
001450484 049__ $$aISEA
001450484 050_4 $$aRC270.3.T65
001450484 08204 $$a616.99/407575$$223/eng/20221102
001450484 1001_ $$aWong, Ching Yee Oliver,$$eauthor.
001450484 24510 $$aPhenotype oncology PET :$$ban instructional casebook /$$cChing Yee Oliver Wong, Dafang Wu.
001450484 264_1 $$aCham :$$bSpringer,$$c[2022]
001450484 264_4 $$c©2022
001450484 300__ $$a1 online resource (xvii, 339 pages) :$$billustrations (some color)
001450484 336__ $$atext$$btxt$$2rdacontent
001450484 337__ $$acomputer$$bc$$2rdamedia
001450484 338__ $$aonline resource$$bcr$$2rdacarrier
001450484 504__ $$aIncludes bibliographical references and index.
001450484 5050_ $$aIntro -- Preface -- Acknowledgments -- Contents -- Chapter 1: Case 1: Double Pulmonary Nodules -- 1.1 Case 1: Interpretation and Teaching -- Reference -- Chapter 2: Case 2: Nodular Sclerosing Hodgkin's Lymphoma -- 2.1 Case 2: Interpretation and Teaching -- 2.2 Assessment of Treatment Response -- Reference -- Chapter 3: Case 3: Transformation in Non-Hodgkin's Lymphoma -- 3.1 Case 3: Interpretation and Teaching -- Reference -- Chapter 4: Case 4: Metabolic Phenotypes in Different Neoplasms -- 4.1 Case 4: Interpretation and Teaching -- Reference
001450484 5058_ $$aChapter 5: Case 5: Marrow Involvement in Non-Hodgkin's Lymphoma -- 5.1 Case 5: Interpretation and Teaching -- Reference -- Chapter 6: Case 6: Hip Pain in Lymphoma -- 6.1 Case 6: Interpretation and Teaching -- Reference -- Chapter 7: Case 7: Prostate Cancer-Specific PET Agent with Rising PSA -- 7.1 Case 7: Interpretation and Teaching -- Reference -- Chapter 8: Case 8: Brain Tumor Evaluation -- 8.1 Case 8: Interpretation and Teaching -- Reference -- Chapter 9: Case 9: Metabolic Phenotype in a Slowly Growing Lung Cancer -- 9.1 Case 9: Interpretation and Teaching -- Reference
001450484 5058_ $$aChapter 10: Case 10: Metabolic Phenotype in Lung Metastasis from Colon Cancer -- 10.1 Case 10: Interpretation and Teaching -- Reference -- Chapter 11: Case 11: PET and Bone Scans in Non-Small Cell Lung Cancer -- 11.1 Case 11: Interpretation and Teaching -- Reference -- Chapter 12: Case 12: Neuroendocrine Cancer of the Ileum -- 12.1 Case 12: Interpretation and Teaching -- Reference -- Chapter 13: Case 13: Coexisting Different PET Tumor Phenotypes -- 13.1 Case 13: Interpretation and Teaching -- Reference -- Chapter 14: Case 14: COVID-19 Vaccination and Lung Nodules
001450484 5058_ $$a14.1 Case 14: Interpretation and Teaching -- Reference -- Chapter 16: Case 16: Breast and Ovarian Uptake -- 16.1 Case 16: Interpretation and Teaching -- References -- Chapter 17: Case 17: Rising PSA in Radical Prostatectomy for Prostate Cancer -- 17.1 Case 17: Interpretation and Teaching -- Reference -- Chapter 18: Case 18: Concurrent Lung and Brain Metastatic Cancer -- 18.1 Case 18: Interpretation and Teaching -- Reference -- Chapter 19: Case 19: Tumor Phenotypes in Metastatic Prostate Cancer -- 19.1 Case 19: Interpretation and Teaching -- Reference
001450484 5058_ $$aChapter 20: Case 20: Metastatic Recurrent Melanoma -- 20.1 Case 20: Interpretation and Teaching -- Reference -- Chapter 21: Case 21: Post-prostatectomy for Prostate Cancer with Rising PSA -- 21.1 Case 21: Interpretation and Teaching -- Reference -- Chapter 22: Case 22: Left Adrenal Mass -- 22.1 Case 22: Interpretation and Teaching -- Reference -- Chapter 23: Case 23: Cutaneous T-Cell Lymphoma -- 23.1 Case 23: Interpretation and Teaching -- Reference -- Chapter 24: Case 24: Active Myeloma Versus Schmorl's Node -- 24.1 Case 24: Interpretation and Teaching -- Reference
001450484 506__ $$aAccess limited to authorized users.
001450484 520__ $$aThis casebook details key information and findings in PET oncology imaging. PET CT has been increasingly utilized in clinical practice for diagnostic evaluation, initial staging and restaging of malignancies, and plays an important role in optimal patient care. Although F-18 fluorodeoxyglucose (FDG) is still the dominant radioactive tracer in oncology PET imaging services, a handful of new tracers have recently gained the US FDA approval, such as Ga-68 or Cu-64 DOTATATE for carcinoid/neuroendocrine tumors, and F-18 Fluciclovine (AXUMIN) and PSMA for recurrent or metastatic prostate cancers. Clinical interpretation of PET CT oncology scans is often challenging, due to the specific nature of these positron emission radioactive tracers, variable background tracer activities in different organs/tissues with normal variants, complex tumor biology, and wide-ranged treatment responses, especially with emerging and new molecular and immune therapy agents. This book serves as a hands-on casebook on how to interpret oncologic PET CT studies in clinical services with a special emphasis on phenotypic nature of oncologic imaging. Clinical cases are presented in a way that is familiar to physicians from their training in nuclear medicine services. Each case starts with key clinical information or background, followed by well-displayed PET CT images, along with pertinent questions highlighting the key findings and explanation, as well as the importance in diagnosis and clinical implications on separate pages. Clinical and imaging key findings and final impressions are highlighted throughout along with qualitative and quantitative demonstrations of phenotypic nature of modern PET imaging. Written by two nuclear medicine PET specialists with decades of first-hand clinical experience, this is an ideal guide for nuclear medicine attending physicians, diagnostic radiologists, medical and surgical oncologists, and relevant trainees.
001450484 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed November 2, 2022).
001450484 650_0 $$aCancer$$xTomography.
001450484 650_0 $$aTomography, Emission.
001450484 655_0 $$aElectronic books.
001450484 7001_ $$aWu, Dafang,$$eauthor.
001450484 77608 $$iPrint version: $$z303109736X$$z9783031097362$$w(OCoLC)1322365882
001450484 852__ $$bebk
001450484 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-09737-9$$zOnline Access$$91397441.1
001450484 909CO $$ooai:library.usi.edu:1450484$$pGLOBAL_SET
001450484 980__ $$aBIB
001450484 980__ $$aEBOOK
001450484 982__ $$aEbook
001450484 983__ $$aOnline
001450484 994__ $$a92$$bISE